BridgeBio Pharma (BBIO) Short-term Investments (2019 - 2026)

BridgeBio Pharma's Short-term Investments history runs 8 years deep, the most recent figure standing at $60.3 million for Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $60.3 million; the TTM figure through Mar 2026 stood at $60.3 million (changed N/A YoY), while the FY2025 annual figure was $17.4 million, changed N/A from the prior year.
• Short-term Investments came in at $60.3 million for Q1 2026 at BridgeBio Pharma, up from $17.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $261.9 million in Q1 2022 to a low of $3.0 million in Q3 2025.
• A 5-year average of $77.1 million and a median of $48.4 million in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments soared 21329.38% in 2022 and plunged 94.31% in 2025, its largest moves.
• BridgeBio Pharma's Short-term Investments stood at $37.9 million in 2022, then surged by 55.42% to $58.9 million in 2023, then surged by 136.49% to $139.4 million in 2024, then slumped by 87.55% to $17.4 million in 2025, then jumped by 247.26% to $60.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $60.3 million, $17.4 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison